We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Researchers Raise Concerns over FDA’s Expedited Approval Pathway
Researchers Raise Concerns over FDA’s Expedited Approval Pathway
Two new studies point to concerns over the FDA’s increasing use of expedited development and approval pathways — programs that rely on early-stage trials that produce less robust data.